Cell of origin for malignant gliomas and its implication in therapeutic development.
Level 5 - mechanism / opinion, no new human data
Narrative review of mechanistic and preclinical research without systematic methodology
PubMed 25635044 · doi:10.1101/cshperspect.a020610
What was done
The authors reviewed literature investigating the cell of origin in malignant gliomas, focusing on evidence for neural stem cells, astrocytes, and oligodendrocyte precursor cells, while discussing technical considerations for future research and translational therapeutic applications.
What was found
The abstract reports no numerical metrics or statistical findings. It notes that evidence supports neural stem cells, astrocytes, and oligodendrocyte precursor cells as possible cells of origin for malignant gliomas.
Why it matters
Identifying the precise cell types from which malignant gliomas originate can clarify disease mechanisms and highlight leverage points for targeted therapeutic development.
Limits
The abstract provides a purely narrative overview without primary clinical data, systematic review methodology, or quantitative results.
Cited by
- context Astrocytes give rise to brain cancer.